Dendreon’s Provenge steps gingerly on path to Medicare/Medicaid reimbursement
This article was originally published in Scrip
Executive Summary
As a result of the release of the Agency for Healthcare Research and Quality’s (AHRQ) 54-page draft report on the outcomes of its prostate cancer autologous vaccine, Provenge (Sipuleucel-T), Dendreon’s stock price hardly moved on the news that the agency rated its data on the treatment only of “moderate” quality.
You may also be interested in...
Gender Diversity In Pharma: Caught Between Desire And Reality
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.
Women In High Places: Slow Progress In Pharma
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.
Stock Scan April 2018: Pharma's Fizz Falls Flat
In a flat month, the market value of big pharma changed little overall. But the balance of power in immuno-oncology did shift significantly.